NCT05101356: A Cancer Vaccine (Labvax 3(22-23) and GM-CSF for the Treatment of Advanced Stage Adenocarcinoma

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known untreated, active brain and/or leptomeningeal metastases

Comments are closed.

Up ↑